Factors to watch out for in Q1 would be margin, contract research business, R&D cost, pricing pressure in legacy API biz (especially statins), recovery in branded formulation (was flat in Q4 due to restructuring) and pick up in Middle East market (did well in Q4).
first published: Jul 20, 2016 03:34 pm
A collection of the most-viewed Moneycontrol videos.
Indian stocks Vs Gold, Silver, Global equities: Manish Chokhani on where to sow, where to harvest
Can Nifty Reclaim 25,400 After Strong Comeback; Infosys, Axis, Eternal In Focus|Opening Bell Live
Sensex, Nifty resume rally after 2-day pause, financials shine bright | Closing Bell
Maran Govindasamy of Unifi Capital on Investment Insights from India’s Consumption Story
